Profiling of recurrent head and neck squamous cell cancers
Research type
Research Study
Full title
Profiling of recurrent head and neck squamous cell cancers
IRAS ID
340790
Contact name
David J Thomson
Contact email
Sponsor organisation
University of Manchester
Duration of Study in the UK
0 years, 10 months, 12 days
Research summary
While a large proportion of patients with head and neck squamous cell carcinoma (HNSCC) are cured with intensive treatment, about 40% experience treatment failure, with the head / neck area the most common site of failure. While several patient and tumour-factors are prognostic and predictive of failure, recent understandings of cancer genomics have not translated into the clinic to identify patients with HNSCC as having a high risk of treatment failure and/or guide treatment. This study, funded by Cancer Research UK RadNet Seed Funding, will use genomic, proteomic and transcriptomic techniques to profile tumours and develop new biomarkers with the aim of aiding treatment personalisation in HNSCC patients. This will enable clinicians to make treatment decisions from a knowledge base informed by likely response of an individual tumour to radiotherapy and may serve as an exemplar that could be applied to cancers in other tissue types. To do this, the study will analyse surplus FFPE tissue at the University of Manchester, removed as part of standard of care procedure, from approximately 100 patients diagnosed with recurrent disease at Trusts across Greater Manchester, Cheshire and Liverpool.
This study, funded by Cancer Research UK RadNet Seed Funding, will use genomic, proteomic and transcriptomic techniques to profile tumours and develop new biomarkers with the aim of aiding treatment personalisation in HNSCC patients. This will enable clinicians to make treatment decisions from a knowledge base informed by likely response of an individual tumour to radiotherapy and may serve as an exemplar that could be applied to cancers in other tissue types. To do this, the study will analyse surplus FFPE tissue at the University of Manchester, removed as part of standard of care procedure, from approximately 50 patients diagnosed with recurrent disease at Trusts across Greater Manchester.REC name
East of England - Essex Research Ethics Committee
REC reference
24/EE/0224
Date of REC Opinion
24 Sep 2024
REC opinion
Favourable Opinion